Long-term effects of treatment and response in patients with chronic hepatitis C on quality of life. An international, multicenter, randomized, controlled study

BMC Gastroenterology

Research Article

Geert Bezemer¹  Robert J de Knegt¹  Elke Verheij-Hart¹  Solko W Schalm¹  Bettina E Hansen¹  Arthur R Van Gool²  Francesco Negro³  Stefan Zeuzem⁴  Yoav Lurie⁵  Carlo Ferrari⁶  Martin Lagging⁷  Juan I Esteban⁸  Jean-Michel Pawlotsky⁹  Avidan U Neumann^1,10 

[1] Dpt. Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands;Dpt. Gastroenterology & Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands;Yulius Academy, Yulius, Organization for Mental Health, Rotterdam, The Netherlands;Dpt. Gastroenterology & Hepatology, Hospital University of Genève, Genève, Switzerland;Dpt. Gastroenterology & Hepatology, Johann Wolfgang Goethe Hospital, Frankfurt, Germany;Dpt. Gastroenterology, Sourasky Medical Center, Tel-Aviv, Israel;Dpt. Infectious Diseases and Hepatology, Azienda Ospedaliera di Parma, Parma, Italy;Dpt. Infectious Diseases, University of Gothenburg, Gothenborg, Sweden;Dpt. Internal Medicine-Hepatology, Hospital General Vall d'Hebron, Barcelona, Spain;Dpt. Virology, Hopital Henri Mondor - Université Paris XII, Creteil, France;Mina and Everard Goodman Faculty of Life Sciences, Bar-Ilan University, Ramat-Gan, Israel;

关键词: health related quality of life;    hepatitis C;    peginterferon;   

DOI  :  10.1186/1471-230X-12-11

 received in 2011-07-28, accepted in 2012-01-31,  发布年份 2012

来源: Springer

【 摘 要 】

BackgroundHepatitis C decreases health related quality of life (HRQL) which is further diminished by antiviral therapy. HRQL improves after successful treatment. This trial explores the course of and factors associated with HRQL in patients given individualized or standard treatment based on early treatment response (Ditto-study).MethodsThe Short Form (SF)-36 Health Survey was administered at baseline (n = 192) and 24 weeks after the end of therapy (n = 128).ResultsAt baseline HRQL was influenced by age, participating center, severity of liver disease and income. Exploring the course of HRQL (scores at follow up minus baseline), only the dimension general health increased. In this dimension patients with a relapse or sustained response differed from non-responders. Men and women differed in the dimension bodily pain. Treatment schedule did not influence the course of HRQL.ConclusionsMain determinants of HRQL were severity of liver disease, age, gender, participating center and response to treatment. Our results do not exclude a more profound negative impact of individualized treatment compared to standard, possibly caused by higher doses and extended treatment duration in the individualized group. Antiviral therapy might have a more intense and more prolonged negative impact on females.

【 授权许可】

Unknown   
© Bezemer et al; licensee BioMed Central Ltd. 2012. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.